Szyndralewiez, Cédric

Critical role of nox4-based nadph oxidase in glucose-induced oxidative stress in the kidney: Implications in type 2 diabetic nephropathy

Sedeek, M., Callera, G., Montezano, A., Gutsol, A., Heitz, F., Szyndralewiez, C., Page, P., Kennedy, C. R. J., Burns, K. D., Touyz, R. M., et al. (2010) · American Journal of Physiology-Renal Physiology

Chronic Kidney Disease and DiabetesNitric Oxide and Endothelin Effects

Cited by 396

Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent

Aoyama, T., Paik, Y.-H., Watanabe, S., Laleu, B., Gaggini, F., Fioraso-Cartier, L., Molango, S., Heitz, F., Merlot, C., Szyndralewiez, C., et al. (2012) · Hepatology

Liver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

Cited by 336

Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo

Jiang, J. X., Chen, X., Serizawa, N., Szyndralewiez, C., Page, P., Schröder, K., Brandes, R. P., Devaraj, S., & Török, N. J. (2012) · Free Radical Biology and Medicine

Liver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

Cited by 251

First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis

Laleu, B., Gaggini, F., Orchard, M., Fioraso-Cartier, L., Cagnon, L., Houngninou-Molango, S., Gradia, A., Duboux, G., Merlot, C., Heitz, F., et al. (2010) · Journal of Medicinal Chemistry

Heterocyclic Compound Synthesis and BioactivityInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 243

Targeting nadph oxidase with a novel dual nox1/nox4 inhibitor attenuates renal pathology in type 1 diabetes

Gorin, Y., Cavaglieri, R. C., Khazim, K., Lee, D.-Y., Bruno, F., Thakur, S., Fanti, P., Szyndralewiez, C., Barnes, J. L., Block, K., et al. (2015) · American Journal of Physiology-Renal Physiology

Chronic Kidney Disease and DiabetesNitric Oxide and Endothelin Effects

Cited by 183

Therapeutic potential of nadph oxidase 1/4 inhibitors

Teixeira, G., Szyndralewiez, C., Molango, S., Carnesecchi, S., Heitz, F., Wiesel, P., & Wood, J. M. (2017) · British Journal of Pharmacology

Redox biology and oxidative stressNeutrophil, Myeloperoxidase and Oxidative Mechanisms

Cited by 163

The nox4 inhibitor gkt137831 attenuates hypoxia-induced pulmonary vascular cell proliferation

Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M. (2012) · American Journal of Respiratory Cell and Molecular Biology

Pulmonary Hypertension Research and TreatmentsVascular Anomalies and Treatments

Cited by 146

Targeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism

Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., et al. (2011) · PLoS ONE

Angiogenesis and VEGF in CancerNitric Oxide and Endothelin Effects

Cited by 143

Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual nox4/nox1 inhibitors

Gaggini, F., Laleu, B., Orchard, M., Fioraso-Cartier, L., Cagnon, L., Houngninou-Molango, S., Gradia, A., Duboux, G., Merlot, C., Heitz, F., et al. (2011) · Bioorganic & Medicinal Chemistry

Heterocyclic Compound Synthesis and BioactivitySynthesis and Characterization of Heterocyclic Compounds

Cited by 79

Pre‐clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis

Thannickal, V. J., Jandeleit‐Dahm, K., Szyndralewiez, C., & Török, N. J. (2023) · Journal of Cellular and Molecular Medicine

Liver physiology and pathologyInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 65